Impact of Clinical Pharmacist Consultation Visits at Ministry of Health Hospitals in Saudi Arabia: Clinical Pharmacy Services and Pharmacy Workforce

2017 ◽  
Vol 3 (3) ◽  
pp. 154-160
Author(s):  
Yousef Ahmed Alomi ◽  
Nasser Aldosori ◽  
Malika Alhadab ◽  
Nahedh Rashed Alotaibi ◽  
Nisreen Al- Shubbar ◽  
...  
2020 ◽  
Vol 21 (2) ◽  
pp. 531-538
Author(s):  
Ahmed M Kabel ◽  
Morouj M Bakr ◽  
Abeer M Alshanbari ◽  
Shahad M Alwagdani ◽  
Hanan A Altalhi ◽  
...  

2020 ◽  
Vol 9 (2) ◽  
pp. 48-50
Author(s):  
Yousef Ahmed Alomi ◽  
Nezar Adnan Yahya Khayat ◽  
Yasir Abdulraheem Bamagaus ◽  
Sultan Mesfer Aljumayi ◽  
Hani Mohammed Ali Jumah ◽  
...  

2020 ◽  
Vol 11 (SPL4) ◽  
pp. 745-750
Author(s):  
Bushan Kumar GG ◽  
Jyothi Singamsetty ◽  
Rajasekhar K V ◽  
Sahitya Meda

Clinical pharmacy services are the services provided by the pharmacists to promote patient care, optimizes medication therapy, promote health and disease prevention. This prospective cross sectional study was conducted in tertiary care hospital over a period of 6 months. This collected data is checked for their appropriateness of any prescription related errors and DRPs were identified. Results obtained were assessed to determine the influence of Clinical pharmacist services. Majority of the prescriptions were with 5-9(62.5%) drugs. The majority of co-morbidities among 125 enrolled patients in age group of 60-70, 55 patients were with 3-4 co-morbidities. Among 125 prescriptions around 12 prescriptions were identified with 622 drug interactions. Among 125 patients 2 (0.277) adverse drug reactions were observed and according to Naranjo's probability assessment scale these adverse drug reactions were mild and 15(2.08%) dispensing errors, 10(1.386%) prescription errors where majority of prescription errors are due to missed written frequencies in the prescriptions. 5(0.693%) administration errors, 5 (0.693%)untreated indications were observed. Presence of clinical pharmacist in hospital settings can reduce drug related problems and they can assist other staff in improving patient care.


2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Aslınur Albayrak ◽  
Bilgen Başgut ◽  
Gülbin Aygencel Bıkmaz ◽  
Bensu Karahalil

Abstract Background Critically ill patients treated in the intensive care units (ICUs) often suffer from side effects and drug-related problems (DRPs) that can be life-threatening. A way to prevent DRPs and improve drug safety and efficacy is to include clinical pharmacists in the clinical team. This study aims to evaluate the classification of drug-related problems and the implementation of clinical pharmacy services by a clinical pharmacist in the ICU of a university hospital in Turkey. Methods This study was carried out prospectively between December 2020 and July 2021 in Gazi University Medical Faculty Hospital Internal Diseases ICU. All patients hospitalized in the intensive care unit for more than 24 h were included in the study. During the study, the clinical pharmacist's interventions and other clinical services for patients were recorded. DRPs were classed according to the Pharmaceutical Care Network Europe V.8.02. Results A total of 151 patients were included during the study period corresponding to 2264 patient-days. Patients with DRPs had a longer hospital stay and a higher mortality rate (p < 0.05). 108 patients had at least one DRP and the total number of DRPs was 206. There was an average of 1.36 DRPs per patient, 71.5% of patients experienced DRP and 89.22 DRPs per 1000 patient-days. A total of 35 ADEs were observed in 32 patients. ADE incidence was per 1000 patient-days 15.45. ADEs were caused by nephrotoxicity (48.57%), electrolyte disorders (17.14%), drug-induced thrombocytopenia (17.14%), liver enzyme increase (8.57%) and other causes (8.57%). Drug selection (40.29%) and dose selection (54.36%) constituted most of the causes of DRPs. Dose change was the highest percentage of planned interventions with a rate of 56.79%. Intervention was accepted at a rate of 90.8% and it was fully implemented. Conclusion In this study, the importance of the clinical pharmacist in the determination and analysis of DRPs was emphasized. Clinical pharmacy services like the one described should be implemented widely to increase patient safety.


Sign in / Sign up

Export Citation Format

Share Document